Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Editas Medicine is a clinical-stage biotechnology company focused on translating the power and promise of genome editing technologies into a robust pipeline of treatments for people living with serious diseases around the world. Headquartered in Cambridge, MA, Editas Medicine is pioneering the development of both in vivo (directly in the body) and ex vivo (outside the body) CRISPR-based medicines. Their lead programs target severe hematologic diseases like sickle cell disease and beta-thalassemia, with ongoing research in other therapeutic areas including oncology and ocular diseases. The company aims to deliver durable, life-changing therapies by precisely editing DNA.
The headquarters serves as the primary center for research and development, corporate operations, clinical development, and strategic decision-making, focusing on advancing CRISPR-based gene editing therapies.
State-of-the-art laboratory facilities designed for gene editing research, process development, manufacturing sciences, and analytical capabilities. The building supports advanced scientific discovery, collaboration, and houses the company's leadership.
Editas Medicine fosters a dynamic, science-driven, and collaborative work environment. The culture emphasizes innovation, a commitment to patients, scientific rigor, and teamwork, attracting talent passionate about pioneering new medicines.
Its Cambridge location (Kendall Square vicinity) provides unparalleled access to a rich ecosystem of world-class academic institutions, research organizations, a highly skilled talent pool, and venture capital, crucial for a leading-edge biotechnology company.
Editas Medicine's primary operational footprint, including research, development, and corporate functions, is centered in the United States (Cambridge, MA, and Boulder, CO). While direct office presence is US-based, the company's reach is global through its clinical trials, which may be conducted at sites in multiple countries. Editas Medicine also engages in global collaborations and partnerships to advance its mission of bringing gene editing therapies to patients worldwide.
11 Hurley Street
Cambridge
MA
USA
Address: 6100 Lookout Rd, Suite 100, Boulder, CO 80301
This location allows Editas Medicine to leverage the biotechnology and scientific talent pool in the Boulder/Denver metropolitan area and may support specific research programs, technical operations, or collaborations.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Editas Medicine' leadership includes:
Editas Medicine has been backed by several prominent investors over the years, including:
Over the past 12 months (May 2023 - May 2024), Editas Medicine has strategically strengthened its executive leadership team with key appointments in legal and business development, underscoring its commitment to advancing its pipeline and corporate strategy. No major C-level departures resulting in immediate replacement announcements were noted in this period.
Discover the tools Editas Medicine uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Editas Medicine primarily uses the email domain @editasmed.com for its corporate communications. The most commonly observed email format is the employee's first initial followed by their last name.
firstinitiallast@editasmed.com
Format
jdoe@editasmed.com
Example
85%
Success rate
Editas Medicine Press Release (GlobeNewswire) • May 9, 2024
Editas Medicine reported its financial results for the first quarter of 2024 and provided a business update, highlighting progress in its EDIT-301 program for sickle cell disease and beta-thalassemia, including patient dosing milestones and upcoming data readouts. The company reiterated its strategic priorities and pipeline advancement....more
Editas Medicine Press Release (GlobeNewswire) • February 28, 2024
The company announced its financial results for Q4 and full-year 2023, along with updates on its clinical programs, particularly focusing on the advancement of EDIT-301 (reni-cel) for severe sickle cell disease and transfusion-dependent beta thalassemia....more
Editas Medicine Press Release (GlobeNewswire) • December 11, 2023
Editas Medicine shared encouraging initial safety and efficacy data from its Phase 1/2 RUBY trial for severe sickle cell disease and EdiTHAL trial for transfusion-dependent beta-thalassemia. The data showed successful engraftment of reni-cel and early indicators of clinical benefit, including increased fetal hemoglobin levels and improved anemia....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Editas Medicine, are just a search away.